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Objectives: to examine coagulation, fibrinolysis, and platelet activity in patients with peripheral vascular disease (PVD).
Design: fifty consecutive PVD patients and 50 healthy volunteers. (Prospective comparative study.)
Materials and methods: P-selectin expression in non-fixed, whole blood was measured flow cytometrically on non-
stimulated and ADP- and TRAP-6-stimulated samples. Plasma fibrinogen, von Willebrand factor (vWF), tissue plas-
minogen activator (tPA), and plasminogen activator inhibitor-1 were determined using standard techniques. Disease
severity was stratified on the basis of the ankle-brachial pressure index (ABPI) and the angiographic data were assessed
using the Bollinger score.
Results: coagulation and fibrinolysis parameters as well as the P-selectin expression on both stimulated and non-
stimulated platelets were significantly increased in patients vs controls (all p<0.01). The respective sensitivity and
specificity were as follows: P-selectin expression (81%, 94%), vWF (72%, 86%), fibrinogen (64%, 98%), PAI-1 (44%,
90%), tPA (15%, 100%). P-selectin expression on TRAP-6-stimulated MP correlated with disease severity (r=0.40,
p<0.01).
Conclusions: these findings support the concept of ongoing thrombogenesis in the subclinical progression of PVD and
demonstrate the high diagnostic sensitivity of flow cytometric analysis of platelet activation.
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Introduction The aim of the present study is to further elucidate
haemostatic imbalance in PVD and evaluate a novel
Peripheral vascular disease (PVD) is associated with flow cytometric quantitative assay for P-selectin.
a high incidence of fatal thrombotic events.1–4 It is well
established that patients with PVD exhibit ab-
normalities of both coagulation and fibrinolysis.5–11
The role of platelet activation in PVD remains con- Materials and Methods
troversial.12–16 Platelet aggregation studies17 and in-
vestigations analysing platelet activation markers, Study population
such as platelet factor 4 (PF4), -thromboglobulin and
thromboxane A2, have yielded contradictory results,18,19 Fifty consecutive patients with symptomatic PVD (42
as have the flow cytometric protocols developed up men, eight female) were included in the study. The
to present.20 In contrast, platelet hyperreactivity (i.e. study was performed with informed consent and with
increased flow-mediated adhesion and aggregation) the approval of the university ethics committee.
in PVD patients has been verified consistently with Patients were given a questionnaire based on WHO
stagnation point adhesio-aggegometry (SPAA).7,21 Al- recommendations for the detection of cardiovascular
though glycoprotein IIb/IIIa interactions with fib- disease.23 Risk profile and concomitant medication in
rinogen appear to be involved, the exact mechanisms the PVD group and in the control group are shown in
underlying these findings remain to be clarified.22 Table 1. Patients with malignancies, systemic diseases,
and end-stage renal or liver failure were excluded
from the study. Fifty consecutive healthy blood donors∗ Please address all correspondence to: M. Koksch, Rue de Sees 21,
D-47918 Toenisvorst, Germany. (40 men, 10 women) served as controls. In controls
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Table 1. Demographic details of subjects. Sigma, Deisenhofen, Germany). Platelet count was
adjusted to approximately 20 000 platelets/l. Aliquots
Risk profile for Frequency Frequency in of the platelet suspension were activated for 10 mincardiovascular disease in controls PVD patients
at 37 °C with 5 M ADP (final concentration, Sigma,
Smoking 12 (24%) 39 (78%) Deisenhofen, Germany) and with 10 M thrombin-
Hypertension 0 (0%) 34 (68%) receptor-activating peptide 6 (final concentration,Hypercholesterolemia 7 (14%) 24 (48%)
Diabetes mellitus 0 (0%) 17 (34%) TRAP-6, Bachem, Bubendorf, Switzerland). Native
Hyperuricaemia 0 (0%) 12 (24%) nonactivated whole blood from the same sampling
Evidence of concomitant vascular disease served as control. The aliquots were incubated at 37 °C
Transient ischaemic attacks and/or 0 (0%) 23 (46%) with saturating concentrations of a murine PE-labelledstroke
anti-gpIIb/IIIa monoclonal antibody (clone P2, CD41,Angina pectoris and/or documented 0 (0%) 14 (28%)
myocardial infarction Beckman Coulter, Krefeld, Germany) and a murine
Concomitant cerebro- and coronary 0 (0%) 8 (16%) FITC-labelled anti-GMP 140 monoclonal antibodyartery disease
(clone CLB-Thromb/6, CD62P, Beckman Coulter, Kre-
Medication
feld, Germany). Platelet activation and staining wereAcetylsalicylic acid 0 (0%) 20 (40%)
Calcium channel antagonists 0 (0%) 23 (46%) stopped after 5 min by incubation with 2 ml of 4 °C
Angiotensin-converting enzyme 0 (0%) 16 (32%) HBSS buffer.
inhibitors
Nitrates 0 (0%) 11 (22%)
-blockers 0 (0%) 7 (14%)
Diuretics 0 (0%) 5 (10%)
Flow cytometric analysis
the absence of asymptomatic PVD was verified by an A Beckman Coulter Epics XL flow cytometer equipped
APBI of >0.9 and the WHO questionnaire. with standard filters for FITC and PE fluorescence
PVD was assessed clinically according to the guide- analysis, and an XL System II software R 3.0 (Beck-
lines of the European Working Group on Critical Leg man Coulter, Fullerton, FL, U.S.A.) was used for meas-
Ischaemia.12 Disease severity was stratified on the basis urements. In this whole blood assay platelets,
of ankle-brachial pressure indices (ABPI) into mod- microparticles (MP), and platelet-containing ag-
erate (ratio 0.4–0.8; n=21; claudication) and severe gregates were gated in the forward scatter vs FL2
(ratio <0.4; n=29; critical limb ischaemia [CLI]). Sys- (CD41-PE) dotplot based on the characteristic FSC
tolic pressures of the anterior and posterior tibial signal (MP: lower FSC signal than platelets; aggregates:
arteries were recorded with a hand-held doppler ultra- higher FSC signal than platelets) and on the high FL2
sound device. The mean value of both indices of the emission signal. To exclude all CD41-negative events
worst leg was used for stratification. Angiograms were the discriminator was set in Fl2. In the list mode 10 000
assessed semiquantitatively according to the Bollinger platelets were acquired at a flow rate of <500 particles/
score.24 s and subsequently analysed. Values are mean fluor-
escence intensities of CD62P-FITC-labelled platelets,
MP, and aggregates.
For determination of intraindividual variation co-Blood drawing and platelet preparation
efficients freshly taken citrated whole blood of the
same healthy blood donor was analysed on the fol-Fasting blood was drawn in the morning from the
lowing 10 days using the above mentioned protocol.antecubital vein using a 21-gauge needle with minimal
suction and tourniquet use. The first 10 ml were used
for routine laboratory tests. Blood for platelet and
coagulation analysis was then drawn into 10 ml syr- Analysis of coagulation and fibrinolysis parameters
inges containing 3.8% sodium citrate. Plasma was
prepared from the citrated venous blood by differential Enzyme-linked immunosorbent assays were used for
the determination of plasma levels of tissue plasm-centrifugation (4.000 g, 15 min) and stored at −80 °C
until parameter determination. Whole blood for flow inogen activator (t-PA; Immunozym t-PA-active, Im-
muno, Heidelberg, Germany), von Willebrand factorcytometry was stored immediately at 37 °C and pro-
cessed between 15 and 45 min after blood drawing. (vWF; Asserachrom vWF, Boehringer Mannheim,
Mannheim, Germany), and plasminogen activator in-Citrated whole blood was diluted in a Hank’s Balanced
Salt Solution (HBSS, Sigma, Deisenhofen, Germany) hibitor-I (PAI-1; Immunozym PAI-1, Immuno, Hei-
delberg, Germany). Blood for these assays wascontaining 1 mg/ml bovine serum albumin (BSA,
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collected into a 5 ml Stabilyte tube (Sarstedt, Linear regression analysis of TRAP-6-stimulated P-
selectin surface expression on platelets and BollingerNuernbrecht, Germany).
Fibrinogen was measured using the turbidimetric score yielded a significant correlation (Fig. 1). Upon
analysis with non-stimulated and ADP-stimulatedmethod (Multifibren U, Behring, Marburg, Germany)
and antithrombin III and PAI-1 activity using chro- platelets a non-significant correlation was seen (data
not shown).mogenic assays (Berichrom Antithrombin III A and
Berichrom PAI-1, Behring, Marburg, Germany).
Coagulation and fibrinolysis parameters in PVD patients
compared to controls and within patient subgroups
Statistics
Analysis of the group means in the patient comparedData processing and subsequent statistical analysis to the control group (Table 4) yielded a significantwere performed with the SPSS for Windows software increase in plasma levels of the procoagulant proteinspackage (SPSS R6.12, SPSS Software GmbH, Munich, fibrinogen and vWF, whereas no differences in anti-Germany). Depending upon the results of Kol- thrombin III activity were observed. t-PA con-mogorov-Smirnov-test for normal distribution, either centrations in the patient group were more than threeStudent’s t-test or Mann–Whitney U-test for in- times higher than those seen in the control group.dependent samples, were used to study associations Plasma levels of PAI-1, an important inhibitor of fib-between test variables. Data are expressed as mean rinolysis, were twice as high in patients. The previousand standard error of mean (SEM) with respective p- led to a significant reduction in the PAI-1/t-PA ratio.value and 95% confidence intervall. A p-value of <0.05 APTT and prothrombin time were also significantlywas considered significant. higher in the patient group.
The numerical results seen in patients with clau-
dication compared to those with CLI are summarised
in Table 5. The only significant difference was noted
Results for antithrombin III. Hereby, a marked decrease was
observed in the CLI patients. A tendency towards
Platelet function in PVD patients compared to controls increased levels of vWF and decreased PAI-1 levels
and within patient subgroups were also measured for this group.
Significantly higher surface P-selectin expression in
patients was found not only with non-stimulated ali-
quots, but with ADP- or TRAP-6-stimulated aliquots Sensitivity and specificity of clotting parameters and flow
cytometrically measured platelet function parametersas well (Table 2). Significantly higher values of this
activation marker were observed on both non-stim-
For the coagulation and fibrinolysis parameters theulated and stimulated microparticles in patients with
progressive disesase when compared to those with sensitivity and specificity were calculated on the basis
of recognised upper normal values (respective normalclaudication (Table 3). Here also, a tendency towards
higher P-selectin levels was noted for non-stimulated range: fibrinogen 1.8–3.5 g/l; vWF 70–130%; ATIII 70–
130%; PAI-1 <43 mg/l; tPA 1–12 mg/l; aPTT <40 s; PTand ADP-stimulated platelets. Subset analysis of P-
selectin expression on MP, platelets, and aggregates 70–120%). Those for the flow cytometrically measured
platelet P-selectin expression were calculated on theof smokers within the control group and of controls
with moderately elevated plasma total cholesterol basis of the observed normal distribution. In Figure
2 A-D a graphic demonstration of test results for non-levels between 5.7 and 6.1 mmol/l revealed no
significant differences to non-smokers and stimulated platelets (A), vWF (B), fibrinogen (C), and
PAI-1 (D) is provided. The sensitivity and specificitynormolipemics, respectively (data not shown). Fur-
thermore, we also observed no significant differences were as follows: fibrinogen (64%, 98%), vWF (72%,
86%), PAI-1 (44%, 90%), tPA (15%, 100%), ATIII (0%,in same subset analysis of smokers vs non-smokers
and normo- vs hyperlipidemics within the PVD group, 100%), aPTT (10%, 100%), PT (0%, 100%), P-selectin
expression on non-stimulated platelets (81%, 94%), onwith the exception of borderline elevated P-selectin
levels on platelet-containing aggregates of smokers vs ADP-stimulated platelets (60%, 90%), and on TRAP-
6-stimulated platelets (28%, 90%). The coefficient ofnon-smokers (data not shown).
Eur J Vasc Endovasc Surg Vol 21, February 2001
M. Koksch et al.150
Table 2. Group means (standard error of mean) for mean anti-P-selectin FITC fluorescence intensity of platelets, microparticles, and
aggregates of patients with peripheral vascular disease (n=50) and controls (n=50).
Parameters Controls PVD patients p value (95% CI)
Platelets Non-activated 0.43 (0.01) 0.50 (0.01) <0.0001 (−0.09, −0.06)
ADP 0.93 (0.03) 1.31 (0.04) <0.0001 (−0.47, −0.29)
TRAP-6 3.21 (0.14) 3.87 (0.15) 0.002 (−1.08, −0.26)
Microparticles Non-activated 0.49 (0.01) 0.55 (0.01) <0.0001 (−0.08, −0.03)
ADP 0.60 (0.01) 0.65 (0.02) 0.007 (−0.09, −0.02)
TRAP-6 0.70 (0.02) 0.74 (0.02) 0.14 (−0.08, 0.01)
Aggregates Non-activated 0.66 (0.01) 0.73 (0.01) <0.0001 (−0.11, −0.04)
ADP 1.20 (0.05) 1.58 (0.05) <0.0001 (−0.52, −0.24)
TRAP-6 3.78 (0.17) 4.70 (0.19) <0.0001 (−1.42, −0.42)
Table 3. Group means (standard error of mean) for mean anti-P-selectin FITC fluorescence intensity of platelets, microparticles, and
aggregates of patients with peripheral vascular disease stratified into claudication (n=21) and critical limb ischaemia (CLI; n=29).
Parameters Claudication CLI p value (95% CI)
ABPI 0.4–0.8 ABPI <0.4
Platelets Non-activated 0.49 (0.01) 0.50 (0.01) 0.52 (−0.04, 0.02)
ADP 1.28 (0.06) 1.32 (0.05) 0.57 (−0.21, 0.12)
TRAP-6 3.87 (0.25) 3.87 (0.18) 0.99 (−0.62, 0.62)
Microparticles Non-activated 0.52 (0.01) 0.57 (0.02) 0.02 (−0.09, −0.01)
ADP 0.61 (0.02) 0.69 (0.02) 0.01 (−0.15, −0.02)
TRAP-6 0.69 (0.02) 0.80 (0.03) 0.003 (−0.18, −0.04)
Aggregates Non-activated 0.73 (0.02) 0.73 (0.01) 0.79 (−0.06, 0.05)
ADP 0.62 (0.09) 0.56 (0.08) 0.61 (−0.18, 0.29)
TRAP-6 4.62 (0.28) 4.69 (0.26) 0.86 (−0.83, 0.70)
Discussion
To date, flow cytometric studies of platelet activation in
atherosclerosis have been based upon acute coronary
syndromes,25–27 percutaneous transluminal angio-
plasty28–30 or bypass surgery.31,32 Studies of patients
with stable coronary disease, and in patients with
PVD, are rare and yield contradictory results.20 The
same is true for such markers of platelet activation as
PF4, -thromboglobulin, thromboxane A2 and urinary
11-dehydro-TxB2.17–19 In patients with PVD, increased
platelet activity – as reflected by increased PF4 and -
TG plasma concentrations – was found only during
treadmill exercise. Although increased PF4 and -TG
levels could not be verified in patients with stable PVD,19
urinary 11-dehydro-TxB2 levels were significantly
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higher. Upon comparison of a group of PVD patients
Fig. 1. The association of P-selectin surface expression on TRAP-6-
with healthy individuals, Galt et al. detected no dif-stimulated platelets in 50 PVD patients to angiographic findings,
semiquantitatively assessed using the Bollinger score. ferences, either in -TG concentrations or in P-selectin
expression on non-stimulated and ADP-stimulated
platelets.20 The only existing reports on platelet hyper-
reactivity in patients with PVD have been provided byintraindividual variation for multiple flow cytometric
investigations using SPAA,7,21,22 whereby the methodmeasurements (n=10; CIV) for non-stimulated plate-
demonstrated a sensitivity of 95% and a specificitylets and for ADP- and TRAP-stimulated platelets were
6.1%, 19.1%, and 16.8%, respectively. of 93% in the detection of manifest PVD. The exact
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Table 4. Group means (standard error of mean) for coagulation and fibrinolysis parameters of patients with peripheral vascular disease
(n=50) and controls (n=50).
Parameters Controls PVD patients p value (95% CI)
Fibrinogen (g/l) 2.3 (0.1) 3.9 (0.1) <0.0001 (−1.81, −1.28)
von Willebrand factor (%) 94.8 (47.0) 165.3 (45.8) <0.0001 (−82.6, −51.9)
Antithrombin III (%) 104.3 (1.0) 106.8 (1.9) 0.20 (−6.0, 1.32)
PAI-1 (mg/l) 25.7 (1.7) 42.1 (2.7) <0.0001 (−23.4, −10.6)
tPA (mg/l) 2.9 (0.2) 9.2 (0.4) <0.0001 (−7.4, −5.4)
PAI-1 / tPA 9.9 (0.9) 4.9 (0.3) <0.0001 ( 3.0, 7.0)
aPTT (s) 32.0 (0.3) 34.3 (0.9) 0.03 (−3.8, −0.2)
Prothrombin time (%) 93.0 (1.1) 96.0 (1.2) 0.02 (−6.0, −0.5)
Table 5. Group means (standard error of mean) for coagulation and fibrinolysis parameters of PVD patients with claudication (n=21)
and with critical limb ischaemia (CLI; n=29).
Parameters Claudication CLI p value (95% CI)
ABPI 0.4–0.8 ABPI <0.4
Fibrinogen (g/l) 3.9 (0.2) 3.8 (0.2) 0.47 (−0.3, 0,7)
von Willebrand factor (%) 148.1 (12.3) 172.2 (6.1) 0.08 (−52.6, 3.27)
Antithrombin III (%) 112.2 (2.3) 102.4 (2.2) 0.003 ( 3.5, 15.8)
PAI-1 (mg/l) 50.6 (5.3) 38.6 (3.0) 0.055 (−0.3, 25.0)
tPA (mg/l) 9.2 (0.8) 8.9 (0.5) 0.72 (−1.6, 2.3)
PAI-1/tPA 5.8 (0.6) 4.5 (0.3) 0.094 (−0.2, 2.7)
aPTT (s) 34.3 (2.0) 33.8 (0.9) 0.84 (−4.0, 4.8)
Prothrombin time (%) 95.5 (2.1) 98.1 (1.3) 0.23 (−6.6, 1.7)
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Fig. 2. Comparative graphics of normal distribution histograms for mean fluorescence intensity of anti-P-selectin labelled non-stimulated
platelets (A), von Willebrand factor (B), fibrinogen (C), and PAI-1 (D) of patients with peripheral vascular disease (n=50) and controls
(n=50). ( ) PVD patients; (ΕΦ) controls.
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mechanisms underlying this observed platelet ac- The above is supported by our results with co-
agulation and fibrinolysis markers. Significantlytivation, however, remain to be clarified.
In the present study we evaluated a novel, whole higher plasma levels of procoagulant proteins fib-
rinogen and von Willebrand factor, as well as of theblood flow cytometric assay for the analysis of platelet
activity. Surface expression of the activation marker pro- and antifibrinolytic parameters tPA and PAI-1,
were seen in our PVD cohort (Table 4). These data areP-selectin was measured on nonactivated platelets as
well as on platelets after in vitro activation using the in accordance with the results of other investigators
having reported haemostatic dysbalance in suchweak agonist ADP and the strong agonist TRAP-6.
The hexapeptide TRAP-6 activates platelets via the patients.5–11,37,38 Although no significant difference in
mean ATIII activity was seen between patients andthrombin receptor with a comparable efficacy as
thrombin itself but has no influence on the coagulation controls (Table 4), upon subgroup analysis of the PVD
patients we observed a significant decrease in the ATIIIcascade. Therefore, TRAP-6 is very useful to mimic
the thrombin effect on platelets in whole blood assays. activity with increasing disease severity (Table 5), a
finding also reported in the Rotterdam Study.39 OurADP and thrombin receptors are involved in different
signal transduction pathways whereby the former is results may indicate an upregulation of both pro-
coagulant and profibrinolytic factors in early stages ofpreferably linked to the adenylate cyclase and the
latter to the phospholipase C. disease. In more advanced disease, ATIII consumption
may lead to even more pronounced procoagulant ac-Comparison of P-selectin expression density on
platelets, MP, and aggregates yielded highly significant tivity with accelerated thrombin generation and sub-
sequent MP formation; which in turn furtherdifferences for both stimulated and non-stimulated
samples between patients and controls. P-selectin ex- potentiates the atherothrombotic process.
The sensitivity and specificity of the coagulationpression on platelets was associated with disease se-
verity of semiquantitatively assessed angiographic and fibrinolysis markers in the detection of manifest
PVD is similar to those reported by Reininger and co-images (Fig. 1). In contrast to findings reported for
patients with coronary and cerebral artery disease, we workers.7 vWF possessed the highest sensitivity (72%)
and a good specificity (86%). Fibrinogen (64%) andthereby verified markedly enhanced platelet activity
in chronic stable PVD. These findings support the PAI-1 (44%) were less sensitive, but more specific (98%;
90%). On the other hand, with a sensitivity of 81%hypothesis that platelet hyperreactivity is contributory
in the subclinical progression of PVD. This may be and a specificity of 94%, we could validate P-selectin
expression as a useful parameter in the detection ofdue to the generalised nature of the atherosclerotic
process in this patient subgroup. PVD. P-selectin proved as specific, but slightly less
sensitive than SPAA-measured platelet function inThe presence of P-selectin expression on platelet-
derived microparticles may be indicative of additional detecting PVD. However, we feel that this slight dis-
advantage is compensated for by the fact that the flowpathogenetic interactions of platelets with the co-
agulation system. MP are generated from platelets after cytometric assay requires less blood, is more rapid
and – if only non-stimulated platelets are analysed –activation by strong agonists (thrombin, collagen). In
the course of MP formation, portions of the inner is slightly less expensive. The reduced sensitivity of
the in vitro stimulated P-selectin analysis in PVDleaflet of the phospholipid bilayer, which contains
large amounts of negatively charged phospholipids patients may, in part, be due to the observed higher
CIV for multiple measurements. As was the case with(phosphatidylserin), are translocated to the outer
leaflet.33–35 These phospholipids act as binding sites for conventional aggregometry, preactivation appears to
yield less predictable and thus less reproduciblecoagulation factors (factor Va, VIIIa, IXa or Xa), support
the assembly of the tenase and prothrombinase com- results.
This is the first flow cytometric study to verifyplex, and thus may promote the intravascular pro-
coagulant activity to a greater degree than activated platelet activation in PVD. An explanation for the high
discriminatory power of our assay in the detection of(entire) platelets.36 Upon subgroup analysis, although
the patients with CLI had an only moderately increased PVD may be the high degree of standardisation of all
pre-analytical procedures: for example, standardisedplatelet P-selectin expression when compared to those
with claudication, P-selectin expression on MP was blood drawing, specimen handling, 37 °C storage tem-
perature, frequent and exact calibration of the in-appreciably higher in these patients (Table 3). This
finding is in line with the assumption that accelerated strument, and – most important – the use of whole
blood dual colour staining, and no additional sta-thrombogenesis is the last step prior to vessel oc-
clusion. bilisation and/or fixation agents.
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